| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/07/2009 | CA2463294C Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 04/07/2009 | CA2420058C Cyclic peptides having melanocortin-4 receptor agonist activity |
| 04/07/2009 | CA2413190C Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 04/07/2009 | CA2410065C Micellar pharmaceutical compositions for buccal and pulmonary application |
| 04/07/2009 | CA2400554C Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
| 04/07/2009 | CA2372384C Anti-inflammatory bioactive glass particulates |
| 04/07/2009 | CA2361998C Aromatic heterocyclic compounds as anti-inflammatory agents |
| 04/07/2009 | CA2341991C Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists |
| 04/07/2009 | CA2341355C Procedure for the chromatographic purification of insulins |
| 04/07/2009 | CA2339253C Inhibitors of p38 |
| 04/07/2009 | CA2279402C Oil or fat composition containing phytosterol |
| 04/07/2009 | CA2237157C Cyclopeptolide inhibitors of adhesion molecules |
| 04/07/2009 | CA2117492C Bystander suppression of autoimmune diseases |
| 04/02/2009 | WO2009042922A2 Peptide-peptidase inhibitor conjugates and methods of making and using same |
| 04/02/2009 | WO2009042435A1 Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
| 04/02/2009 | WO2009042213A1 Methods of treating or preventing cardiac disease associated with a high fat diet |
| 04/02/2009 | WO2009041714A1 External preparation for free radical diseases |
| 04/02/2009 | WO2009041699A1 Bofutsushosan-containing preparation |
| 04/02/2009 | WO2009041698A1 Bofutsushosan-containing preparation |
| 04/02/2009 | WO2009041567A1 Diaryl ketimine derivative having antagonistic activity on melanin-concentrating hormone receptor |
| 04/02/2009 | WO2009041521A1 Quinolone derivative |
| 04/02/2009 | WO2009041449A1 Antiobesity agent |
| 04/02/2009 | WO2009041037A1 Drug for suppressing pathogen occurring in vivo |
| 04/02/2009 | WO2009040816A1 Methods of treating lysosomal storage disorders |
| 04/02/2009 | WO2009040410A1 Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors |
| 04/02/2009 | WO2009040288A1 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives |
| 04/02/2009 | WO2009040089A2 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents |
| 04/02/2009 | WO2009040088A1 Use of peptide kvlpvpq as a therapeutic agent |
| 04/02/2009 | WO2009040086A2 Use of salusin-alpha as a therapeutic agent |
| 04/02/2009 | WO2009040085A2 Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) |
| 04/02/2009 | WO2009040084A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040083A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040073A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040072A2 Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040071A2 Use of cyclo-rgdfv and optionally angiotensin i as therapeutic agents in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040070A2 Use of helodermin as a therapeutic agent |
| 04/02/2009 | WO2009040069A2 Use of bq-610 alone or in combination with helodermin as a therapeutic agent |
| 04/02/2009 | WO2009040068A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040067A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040051A2 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
| 04/02/2009 | WO2009040050A2 Use of calcitonin as anti-angiogenic agent |
| 04/02/2009 | WO2009040049A2 Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents |
| 04/02/2009 | WO2009040048A2 Use of the c-reactive peptide as a therapeutic agent |
| 04/02/2009 | WO2009040047A2 Therapeutic uses of ghrelin and combinations with stresscopin |
| 04/02/2009 | WO2009040046A2 Use of stresscopin-related peptide as a therapeutic agent |
| 04/02/2009 | WO2009040045A2 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents |
| 04/02/2009 | WO2009040036A2 Use of a galanin peptide as a therapeutic agent |
| 04/02/2009 | WO2009040035A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040034A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040033A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040032A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040031A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040030A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040029A2 Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040028A2 Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040027A1 Use of the peptide stresscopin as a therapeutic agent |
| 04/02/2009 | WO2009040025A2 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |
| 04/02/2009 | WO2009040024A2 Use of bim-23127 and optionally urodilatin as therapeutic agents eg for the treatment of m. tuberculosis infections |
| 04/02/2009 | WO2009040022A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040021A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040020A1 Amylin as a therapeutic agent |
| 04/02/2009 | WO2009040019A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040018A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040017A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040006A1 Spantide for therapeutic uses |
| 04/02/2009 | WO2009040005A2 Use of the peptide rfmwmr as a therapeutic agent |
| 04/02/2009 | WO2009040004A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039996A2 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent |
| 04/02/2009 | WO2009039995A1 Big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039994A1 Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039993A2 Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039992A2 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039991A2 Use of aviptadil as a therapeutic agent |
| 04/02/2009 | WO2009039990A2 Use of icam peptide as a therapeutic agent |
| 04/02/2009 | WO2009039989A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent |
| 04/02/2009 | WO2009039988A2 Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection |
| 04/02/2009 | WO2009039987A1 Use of peptide thr-thr-ser-gln-val-arg-pro-arg as a therapeutic agent |
| 04/02/2009 | WO2009039986A2 Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent |
| 04/02/2009 | WO2009039985A2 Therapeutic uses of urocortin ii |
| 04/02/2009 | WO2009039984A2 Therapeutic uses of urocortin ii and kisspeptin ( 27-54 ) |
| 04/02/2009 | WO2009039983A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039982A2 Use of gip alone or in combination with dynorphin b as a therapeutic agent |
| 04/02/2009 | WO2009039981A2 Use of (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039980A2 Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039979A1 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| 04/02/2009 | WO2009039978A2 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof |
| 04/02/2009 | WO2009039977A2 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection |
| 04/02/2009 | WO2009039976A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039974A2 Use of peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 04/02/2009 | WO2009039973A2 Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 04/02/2009 | WO2009039970A1 Use of bpp-b as a therapeutic agent |
| 04/02/2009 | WO2009039969A2 Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent |
| 04/02/2009 | WO2009039968A2 Use of angiotensin iii as a therapeutic agent in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039966A2 Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039964A2 Use of glucagon-like peptide as a therapeutic agent |
| 04/02/2009 | WO2009039963A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent |
| 04/02/2009 | WO2009039960A1 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent |
| 04/02/2009 | WO2009039959A1 Use of peptide wmnstgftkvcgappc as a therapeutic agent |
| 04/02/2009 | WO2009039958A1 Therapeutic uses of peptides ysaypdsvpmms and wmnstgftkvcgappc |
| 04/02/2009 | WO2009039957A2 Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection |